Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis

This is a Phase 2, randomized, masked, multicenter study to assess the safety and efficacy
of two different doses of CLS-TA in the treatment of subjects with macular edema following
non-infectious uveitis. Each subject will receive a single suprachoroidal injection of
CLS-TA.

The subjects enrolled in this study will be chosen from subjects with macular edema
following non-infectious uveitis. A single injection will be administered via the Clearside
microinjector into the suprachoroidal space. The dose injected will either be 4 mg or 0.8 mg
of CLS-TA in a total volume of 100 μL. The dose they receive will depend on what their
randomization code dictates.

Subjects will be monitored for safety and efficacy for approximately 8 weeks following
treatment.

Inclusion Criteria:

- diagnosis of noninfectious uveitis

- diagnosis of macular edema associated with noninfectious uveitis

Exclusion Criteria:

- any ocular trauma within the immediate 6 months prior to treatment

- any photocoagulation or cryotherapy in the 6 months prior to treatment

- any IVT injection of anti-VEGF treatment in the 2 months prior to treatment

- any eye diseases other than uveitis and ME that could compromise central visual
acuity

- any previous suprachoroidal injection of triamcinolone acetonide in the study eye